dabrafenib和曲美替尼的组合是BRAF突变的黑色素瘤的公认治疗方法。然而,这种方法的有效性可能会受到治疗相关发热综合征的发展的阻碍,这发生在至少50%的治疗患者。如果没有适当的干预,发热综合征有可能恶化,并可导致继发于脱水和相关器官相关并发症的低血压。此外,过早终止治疗可能导致无进展生存期和总生存期减少.尽管现有的指导,对于达拉非尼和曲美替尼相关发热的定义和治疗,文献中仍建议了多种治疗方法.这反映在加拿大癌症中心内部和之间预防和治疗的实践差异中。成立了一个加拿大工作组,并根据证据构建了共识声明,并通过两轮修改的Delphi方法最终确定。这些陈述导致了可以很容易地应用于常规实践的发热治疗算法的开发。加拿大工作组的共识声明为达拉非尼和曲美替尼相关发热的管理提供了实际指导。希望能降低停药率,并最终改善患者的生活质量和癌症相关结果。
The combination of
dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least 50% of treated patients. Without appropriate intervention, pyrexia syndrome has the potential to worsen and can result in hypotension secondary to dehydration and associated organ-related complications. Furthermore, premature treatment discontinuation may result in a reduction in progression-free and overall survival. Despite existing guidance, there is still a wide variety of therapeutic approaches suggested in the literature for both the definition and management of
dabrafenib and trametinib-related pyrexia. This is reflected in the practice variation of its prevention and treatment within and between Canadian cancer centres. A Canadian working group was formed and
consensus statements were constructed based on evidence and finalised through a two-round modified Delphi approach. The statements led to the development of a pyrexia treatment algorithm that can easily be applied in routine practice. The Canadian working group
consensus statements serve to provide practical guidance for the management of
dabrafenib and trametinib-related pyrexia, hopefully leading to reduced discontinuation rates, and ultimately improve patients\' quality of life and cancer-related outcomes.